Inhibition of Bruton’s tyrosine kinase (BTK) using BTK inhibitors (BTKis) is being actively pursued as a novel non-depleting B-cell targeting approach in patients with multiple sclerosis (MS). This evidence concerns the gene BTK and myeloid sarcoma.